B+
Bull case
20%
Probability
Target price
$43.80
+14.9% vs current
KEQU
Kewaunee ScientificANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$35.80
-6.1% vs current
B-
Bear case
30%
Probability
Target price
$30.50
-20.0% vs current
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+40.0
Score
AI commentary
Primary operating evidence is strong, but forward visibility is limited. Secondary coverage reported a 3.4% post-earnings decline and 12.1% one-month decline, while analyst revisions and social coverage are unavailable [#PR-EARNINGS-2026-06-29]. This supports cautious monitoring rather than a high-conviction directional view.
RankAlpha Sentiment Codex - 2026-07-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-15eventNext quarterly report tests project timingHigh impact
The next quarterly update should clarify whether domestic laboratory-project delivery volatility and international shipment disruption are temporary timing issues or evidence of weaker demand [#SEC-8K-2026-06-23].
2026-10-15catalystEarnings digestion and profit conversionHigh impact
FY2026 sales rose 17.3% to $282.0 million, but net earnings and diluted EPS declined; management cited project-timing volatility, lower manufacturing volumes, input costs, and tariff pressure in the Lab Products Group [#SEC-8K-2026-06-23].
2027-07-17catalystNu Aire integration and portfolio breadthHigh impact
Management highlighted continued Nu Aire integration and a broader Lab Products Group portfolio, which could support a steadier earnings mix if execution remains consistent [#SEC-8K-2026-06-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology